vTv Therapeutics Presents Additional Positive Clinical Study Results Supporting the Safety and Efficacy of TTP399 as Adjunctive Therapy in Patients…


Data Reported at EASD Virtual Conference Demonstrate that TTP399 Did Not Increase Plasma or Urine Ketones, Avoiding a Key Limitation to the Development of Oral Adjunctive Therapies for T1D Data Reported at EASD Virtual Conference Demonstrate that TTP399 Did Not Increase Plasma or Urine Ketones, Avoiding a Key Limitation to the Development of Oral Adjunctive Therapies for T1D

View post:
vTv Therapeutics Presents Additional Positive Clinical Study Results Supporting the Safety and Efficacy of TTP399 as Adjunctive Therapy in Patients...

Related Posts